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Abstract
The present study investigated the impact of a Lactobacillus rhamnosus CGMCC1.3724 (LPR) supplementation on weight loss and main-
tenance in obese men and women over 24 weeks. In a double-blind, placebo-controlled, randomised trial, each subject consumed two
capsules per d of either a placebo or a LPR formulation (1·6 £ 108 colony-forming units of LPR/capsule with oligofructose and inulin).
Each group was submitted to moderate energy restriction for the first 12 weeks followed by 12 weeks of weight maintenance. Body
weight and composition were measured at baseline, at week 12 and at week 24. The intention-to-treat analysis showed that after the
first 12 weeks and after 24 weeks, mean weight loss was not significantly different between the LPR and placebo groups when all the sub-
jects were considered. However, a significant treatment £ sex interaction was observed. The mean weight loss in women in the LPR group
was significantly higher than that in women in the placebo group (P¼0·02) after the first 12 weeks, whereas it was similar in men in the two
groups (P¼0·53). Women in the LPR group continued to lose body weight and fat mass during the weight-maintenance period, whereas
opposite changes were observed in the placebo group. Changes in body weight and fat mass during the weight-maintenance period were
similar in men in both the groups. LPR-induced weight loss in women was associated not only with significant reductions in fat mass and
circulating leptin concentrations but also with the relative abundance of bacteria of the Lachnospiraceae family in faeces. The present study
shows that the Lactobacillus rhamnosus CGMCC1.3724 formulation helps obese women to achieve sustainable weight loss.
Key words: Energy restriction: Probiotics: Body composition: Microbiota
The increase in the prevalence of obesity observed over the
last few decades has favoured the numerous investigations
that have contributed to better understand the effects of a
modern lifestyle on energy balance, body composition and
metabolic health. Among the studied potential determinants
of obesity, the intestinal microbiota has been proposed to
have an impact on energy balance in both animals and
humans(1,2).
Microbiota may be perceived as an ‘organ’ that contributes
to the metabolism and plays a role in energy storage. The
human gut microbiota is composed of trillions of bacteria
belonging mainly to two bacterial divisions: Firmicutes and
Bacteroidetes. Although the diet has an impact on the com-
position of the gut microbiota(3–5), these bacteria have been
proposed to participate in the development of obesity and
diabetes(6–8). Animal studies have shown differences in gut
microbiota composition associated with obesity(9). Lean mice
have a higher relative abundance of Bacteroidetes and a
lower abundance of Firmicutes when compared with obese
rodents(9). Inoculation of the gut microbiota of obese mice
into axenic mice has been shown to induce a significant fat
mass gain when compared with that of the gut microbiota of
lean animals into mice(10). These data suggest, at least in
mice, a potential role for gut microbiota in the development
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of obesity. In human subjects, Million et al.(11) have recently
demonstrated an association between Lactobacillus and
weight. They found that certain species of Lactobacillus are
present in normal-weight individuals, while other species of
Lactobacillus are present in obese individuals(11). Unlike in
diabetes(12,13), changes in gut microbiota composition associ-
ated with obesity or weight loss are less clear in humans.
In 2006, Ley et al.(6) showed that after consumption of a
carbohydrate- or fat-restricted low-energy diet, obese subjects
had an increased proportion of Bacteroidetes and a decreased
abundance of Firmicutes in their gut, confirming observation
made in rodents. However, other studies have reported
opposite results or lack of changes in gut microbiota
composition(5,14–16). These differences might be due to
differences in population characteristics and size and method-
ologies used for analysing microbiota composition.
The potential role of gut microbiota in the development
of obesity led several groups to investigate the effects of
probiotic consumption on weight management. Probiotics,
which are bacteria known to confer health benefits on the
host, may modulate the gut microbiota and therefore affect
the energy balance and/or metabolism of the host. The admin-
istration of specific strains of Lactobacillus or Bifidobacterium
has been shown to prevent weight gain in mouse models of
obesity(17). Limited evidence exists on the effect of probiotic
consumption on weight management in humans. Kadooka
et al.(18) reported that a supplementation of fermented milk
with Lactobacillus gasseri SBT2055 for 12 weeks induces signi-
ficant weight loss (about 1 kg) and a decrease in abdominal
visceral and subcutaneous fat mass in overweight men and
women under ad libitum conditions. Recently, a placebo-
controlled, double-blind, cross-over clinical study has shown
that the consumption of two yogurts per d supplemented
with Lactobacillus amylovorus (109 colony-forming units
(cfu)/yogurt) leads to a decrease in total body fat mass(19). Inter-
estingly, Ilmonen et al.(20) showed that nutritional counselling
combined with probiotic treatment (Lactobacillus rhamnosus
GG and Bifidobacterium lactis Bb12) in pregnant women can
reduce the risk of central adiposity at 6 months post-partum.
The aim of the present study was to investigate, for the
first time in human subjects, the effects of probiotic consump-
tion during the energy-restriction and weight-maintenance
phases. For this purpose, the association between Lactobacillus
rhamnosus CGMCC1.3724 (LPR) and a low dose of poly-
saccharides was tested in obese men and women.
Methods
Healthy overweight men and women participated in a
24-week randomised, double-blind, placebo-controlled trial
that was aimed at facilitating body-weight control by using
a two-phase intervention protocol. In phase 1 (weight-loss
period), supervised dietary restriction with or without probio-
tic LPR supplementation was followed over 12 weeks. Phase 2
was a period of weight maintenance with supervision of diet-
ary habits without restriction over 12 weeks during which LPR
or placebo supplementation was continued. The present study
was conducted according to the guidelines laid down in the
Declaration of Helsinki, and all procedures involving human
subjects were approved by the Laval Hospital Ethics Commit-
tee (CER: 20 449) and by Health Canada (144245). Written
informed consent was obtained from all the subjects. The
study was registered at ClinicalTrials.gov (NCT01106924).
Subjects
Subjects were recruited through different media in the
Quebec City area on the basis of the following inclusion and
exclusion criteria that were verified during telephone inter-
views: age between 18 and 55 years; absence of pregnancy,
breast-feeding or menopause (determined by the cessation
of menstruation); stable body weight (body-weight change
,5 kg for 3 months before screening); BMI between 29 and
41 kg/m2; without associated co-morbidities (hypertension
$140/90 mmHg, obstructive sleep apnoea, type 2 diabetes
or CVD, or family history of dyslipidaemia); no abnormal
thyroid hormone levels; no immunocompromised conditions
or anaemia; no use of vitamin and mineral supplementation
within 6 months of screening; no use of medication affecting
body weight, energy expenditure, or glucose control or anti-
biotic treatment for the last 3 months; no smoking, drug or
alcohol (.2 drinks/d) problem; consumption of #5 cups of
coffee/d (1250 ml/d). Participants with allergy to the ingre-
dients in the study product and placebo or experiencing
nausea, fever, vomiting, bloody diarrhoea or severe abdomi-
nal pain or currently participating or having had participated
in another clinical trial during the last 6 months before the
beginning of the present study were excluded. A 2-week
washout period was included in the intervention programme
to eliminate probiotic-containing products in the daily diet
before the initiation of treatment. Participants who met these
criteria were invited to a pre-selection individual meeting
during which body weight and height were measured. They
also received more information about the protocol and
explanations about the dietary and physical activity records
that had to be completed at home. Baseline characteristics of
the participants are given in Table 1. The first step of screening
allowed the recruitment of 153 participants. The participants
were aware of the study objectives, but they were blinded
regarding the supplementation (LPR or placebo) that was
assigned according to the computerised randomisation sys-
tem. After randomisation, blood samples were analysed and
twenty-eight subjects were excluded because of dyslipidaemia
(plasma TAG levels .2·0 mmol/l).
Fig. 1 shows the distribution of subjects within each
study group. The LPR formulation and the placebo were
administered orally. All the participants had to ingest one
capsule 30 min before breakfast and one capsule 30 min
before dinner. The subjects were tested at baseline, at week
12 (after the weight-loss phase) and at week 24 (after the
weight-maintenance phase) of the programme. The partici-
pants arrived at the laboratory at about 08.00 hours, after a
12 h overnight fast, during each testing session, and they had
to abstain from physical exercise for 48 h and from alcohol
intake for 24 h before the testing session. For women, testing
sessions were held during the first 10 d of their menstrual cycle.
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Table 1. Baseline characteristics of the subjects
(Mean values with their standard errors)
Male Female
LPR formulation
(n 62) Placebo (n 63)
LPR formulation
(n 24) Placebo (n 24)
LPR formulation
(n 38) Placebo (n 39)
Mean SE Mean SE Mean SE Mean SE Mean SE Mean SE
Age (years) 35·0 10·0 37·0 10·0 37·0 10·0 38·0 10·0 34·0 10·0 36·0 10·0
Body weight (kg) 95·1 13·9 94·0 14·9 104·3 13·0 103·4 15·0 89·3 11·1 88·2 11·5
BMI (kg/m2) 33·8 3·3 33·3 3·2 34·0 2·8 33·5 3·3 33·6 3·6 33·2 3·2
Waist circumference (cm) 103·3 10·5 103·6 10·9 109·7 8·6 110·0 11·0 99·3 9·6 99·7 8·9
Fat mass (kg) 38·52 8·66 37·41 8·88 34·80 8·26 32·84 9·12 40·80 8·19 40·21 7·55
Fat mass (% of body weight) 40·82 7·68 40·08 8·22 33·11 4·94 31·41 5·26 45·57 4·57 45·41 4·10
Fat-free mass (kg) 52·65 12·03 52·83 12·84 65·87 7·20 66·74 8·03 44·52 5·15 44·28 5·72
Fat-free mass (% of body weight) 55·33 7·93 55·94 8·45 63·44 4·82 64·96 5·14 50·33 4·62 50·39 4·21
Mean daily energy intake (kcal) 2510 676 2362 611 2898 550 2752 479 2265 636 2122 562
Mean daily energy intake (kJ) 10 502 2828 9883 2556 12 125 2301 11 514 2004 9477 2661 8878 2351
REE (kcal/min) 1·22 0·21 1·18 0·20 1·38 0·16 1·34 0·18 1·12 0·16 1·08 0·13
REE (kJ/min) 5·10 0·88 4·94 0·84 5·77 0·67 5·61 0·75 4·68 0·67 4·52 0·54
RQ 0·85 0·09 0·86 0·08 0·88 0·10 0·87 0·08 0·83 0·08 0·85 0·07
HR (bpm) 65·6 6·0 66·0 6·1 65·4 6·4 65·6 5·8 65·6 5·8 66·3 6·4
SBP (mmHg) 118·5 10·5 119·0 9·7 112·3 11·8 119·6 10·4 115·8 8·4 119·0 9·80
DBP (mmHg) 76·4 7·9 76·8 7·7 77·7 8·4 77·7 8·2 75·1 7·4 76·6 7·6
Fasting glucose (mmol/l) 4·9 1·0 5·1 0·8 5·3 0·6 5·5 0·9 4·6 1·2 4·9 0·6
Fasting insulin (pmol/l) 63·5 29·5 63·1 34·6 69·0 27·9 68·7 39·0 60·5 29·8 59·7 32·0
Total cholesterol (mmol/l) 4·6 0·9 4·3 0·8 4·6 0·9 4·1 0·9 4·7 0·8 4·4 0·8
TAG (mmol/l) 1·1 0·4 1·1 0·4 1·3 0·4 1·1 0·4 1·1 0·4 1·0 0·4
LDL (mmol/l) 2·8 0·8 2·5 0·7 2·8 0·8 2·5 0·8 2·7 0·8 2·5 0·7
HDL (mmol/l) 1·3 0·4 1·3 0·3 1·1 0·2 1·1 0·2 1·5 0·4 1·4 0·3
Leptin (ng/ml) 36·5 24·2 36·0 25·2 17·9 12·5 16·5 16·7 48·5 22·6 47·9 21·7
Adiponectin (ng/ml) 8912·7 4243·2 8224·5 3582·7 7575·0 3164·5 7141·2 3079·6 9933·5 4651·9 8824·9 3779·5
Glycerol (mmol/l) 0·06 0·03 0·06 0·03 0·03 0·01 0·03 0·01 0·07 0·03 0·08 0·03
NEFA (mmol/l) 0·46 0·14 0·44 0·17 0·36 0·09 0·36 0·17 0·52 0·14 0·50 0·16
b-Hydroxybutyrate (mmol/l) 57·0 53·6 51·4 53·6 44·3 41·0 57·5 73·9 64·1 59·2 47·1 36·2
LBP (mg/ml) 14·3 7·1 15·7 9·6 12·7 4·7 16·0 12·6 15·5 8·2 15·4 7·4
CRP (mg/l) 4·6 5·2 5·4 6·9 3·9 5·0 3·0 4·1 5·1 5·4 6·8 7·9
LPR, Lactobacillus rhamnosus CGMCC1.3724; REE, resting energy expenditure; RQ, respiratory quotient; HR, heart rate; bpm, beats/min; SBP, systolic blood pressure; DBP, diastolic blood pressure; LBP, lipopolysaccharide-
binding protein; CRP, C-reactive protein.
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Treatment
The probiotic capsules contained a formulation consisting
of 10 mg of a LPR powder providing 1·62 £ 108 cfu, 300 mg
of a mix of oligofructose and inulin (70:30, v/v) and 3 mg of
magnesium stearate. The placebo capsules were of the same
colour and size as the LPR capsules and contained 250 mg of
maltodextrin and 3 mg of magnesium stearate. The subjects
consumed two capsules per d corresponding to an average
of 3·24 £ 108 cfu/d in the probiotic group. When combined
with prebiotics or other probiotics, LPR has been shown to
promote healthy growth in toddlers and to reduce risks of
eczema in infants(21,22).
Daily energy intake and physical activity measurements
A standardised 3 d dietary record(23) was obtained from each
participant. This record was completed at home after the par-
ticipants had received detailed explanations from a dietitian.
A computerised version of the Canadian Nutrition File (version
2005) was used to determine the macro- and micronutrient
content of foods as well as total daily energy intake(24).
This measurement was repeated at the end of the weight-
loss period (phase 1) and the weight-maintenance period
(phase 2). A 3 d physical activity record was also completed
at home on the same days the dietary record was completed.
In addition, the participants completed a 24 h dietary recall
with the assistance of the dietitian every 2 weeks during
phase 1 and every month during phase 2. These records or
recalls provided reference information of each participant to
the dietitian to standardise the counselling and related guide-
lines over the two phases of the intervention programme.
Energy-restricted diet
As has been indicated above, each participant received a
personalised diet plan targeting 2092kJ/d (500kcal/d) energy
restriction for the first 12 weeks of the programme. During
phase 2, each participant received a personalised diet plan
without energy restriction. The energy content of the diets
was determined by a dietitian from the daily energy require-
ment of each participant. The daily energy requirement was
estimated using resting energy expenditure and multiplying
it by an activity factor based on the physical activity record.
Resting energy expenditure was determined after a 12 h over-
night fast in subjects having had rested for at least 15 min in a
standardised supine position. Resting energy expenditure was
measured at baseline and was reassessed after the weight-loss
and weight-maintenance periods using indirect calorimetry.
Specifically, expired air was collected through a mouthpiece
After phase 2
19
After phase 2
20
After phase 2
26
After phase 2
28
After phase 1
31
After phase 1
29
After phase 1
22
After phase 1
23
Twenty-four
 LPR
Twenty-four
placebo
Thirty-eight
LPR
Thirty-nine
placebo
Seventy-
seven
 females
Forty-eight
 males
125 Participants
included
153
Participants
randomised
Twenty-eight
participants
excluded
Fig. 1. Flow chart of the study protocol. (A colour version of this figure can be found online at http://www.journals.cambridge.org/bjn).
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with the nose being clipped. The concentrations of oxygen
(electrochemical oxygen sensor) and CO2 (non-dispersive
IR analysis) were determined using an Uras 10 E device
(Hartmann & Braun), whereas pulmonary ventilation was
assessed using a K520 flow transducer and a Spirometric
module S-430A measurement system (KL Engineering). The
Weir formula(25) was used to determine the energy equivalent
of O2 volume.
The food plan was based on an exchange food group list
adapted from the Meal Planning for People with Diabetes(26).
Apart from the supplement, both the groups were limited
to consume a maximum of four servings of products sup-
plemented with probiotics per week. Each participant met his
or her assigned dietitian every 2 weeks during phase 1 and
every 4 weeks during phase 2. The participants’ compliance
to the diet plan was measured by comparing the prescribed
diet composition (total daily energy intake and macronutrient
composition) with the actual diet composition measured
every 2 weeks by a 24 h dietary recall. The participants’ com-
pliance to the supplementation was measured using the
compliance journal every 2 and 4 weeks during the weight-
loss period and the weight-maintenance period, respectively.
Participants who discontinued taking the treatment (LPR or
placebo) for three consecutive days were excluded.
Anthropometric parameter and body composition
measurements
Body weight, height (light clothes and without shoes) and
waist circumference (directly on the skin) were assessed at
baseline, every 2 weeks during phase 1 as well as at the end
of this phase, and every 4 weeks during phase 2 and at the
end of this phase, except for height(27). BMI was calculated
as body weight divided by height squared (kg/m2). During
each testing session, heart rate, systolic blood pressure and
diastolic blood pressure were assessed in a supine position
after a resting period. Body fat and fat-free mass were
measured by dual-energy X-ray absorptiometry (GE Medical
Systems Lunar) at baseline, at the end of the weight-loss
phase and at the end of the weight-maintenance phase.
Biochemical analyses
Blood samples were collected into EDTA-containing tubes
(Miles Pharmaceuticals) and heparin-containing tubes at
about 08.00 hours following an overnight fast for at least 12 h.
These samples were used for the determination of plasma con-
centrations of glucose, insulin, leptin, lipids, lipoproteins and
inflammatory indicators, which were measured at three time
points (baseline, week 12 and week 24). The concentration of
glucose was measured enzymatically(28), that of insulin was
determined by an electrochemiluminescence immunoassay(29),
that of leptin was determined using an ELISA array (Human
Leptin ELISA Kit; B-Bridge International, Inc.) detecting leptin
levels as low as 0·78 pg/assay and not cross-reacting with
human insulin, proinsulin, glucagon, pancreatic polypeptide
or somatostatin(30). The concentrations of total cholesterol,
phospholipids and TAG were quantified by enzymatic assays.
The concentrations of HDL-cholesterol and LDL-cholesterol
were determined by an immunoinhibition method (HDL-C,
LDLC Direct; BioRad Unassayed Chem). The concentration of
C-reactive protein was measured using an ELISA array
(Human C-Reactive Protein ELISA Kit; EDM Millipore). The
concentration of glycerol was measured using a colorimetric
method, utilising commercially available kits (Randox Labo-
ratories), and that of NEFA was measured using the same
method, utilising commercially available kits (Wako). The
plasma concentration of b-hydroxybutyrate was measured
using an enzymatic assay (Wako). The serum concentration
of LBP was assayed using an ELISA kit (Hycult Biotech).
The plasma concentration of adiponectin was determined
using an ELISA array obtained from Millipore.
In vitro gastrointestinal Lactobacillus rhamnosus
CGMCC1.3724 survival assay
LPR (6 £ 108 cfu) was incubated at 378C in 1 ml of gastric
(0·3 % porcine pepsin þ NaCl 0·55 adjusted at pH 2·5) or
duodenal (0·2 M-phosphate buffer at pH 6·8 þ 0·49 % porcine
bile þ 0·24 % porcine pancreatin) simulated juices in the
presence or not in the presence of 0·01, 0·1 or 1 % of
oligofructose/inulin (70:30, v/v; Beneo). After 30 min of
incubation in the gastric juice, 100ml of the mix were trans-
ferred into the duodenal juice for 90 min. LPR viability was
assessed at 30 and 120 min by plating and growing Lactobacilli
for 48 h under anaerobic conditions on de Man, Rogosa and
Sharpe (MRS) agar medium plates (methods adapted from
Sutter et al.(31)). Cfu were counted and are reported as
cfu/ml of solution.
Sequence-based microbiota analysis
Faecal samples were collected from the placebo-treated and
probiotic-treated subjects at baseline, end of phase 1, and end
of phase 2, and samples were stored at 2808C until analysis.
Frozen faecal samples were reduced to a powder using a cryo-
PREP device (Covaris), and total DNA was extracted using the
QIAamp DNA Stool Mini Kit (QIAGEN), following the manu-
facturer’s instructions, except for the addition of a series of
mechanical disruption steps (11 £ 45 s) using a FastPrep
apparatus and Lysing Matrix B tubes (MP Biochemicals)(32).
PCR amplification was carried out using two sets of primers
targeting the hypervariable regions (V) 1–3 (V123) and 4–6
(V456) of the 16S ribosomal RNA gene. For the amplifica-
tion of the V123 region, a mixture of forward primers
was combined to ensure optimal coverage of bacterial
phylogenetic diversity, as described previously(33). The
primers were designed according to Hamady et al.(34):
V123 forward primer 1, 50-CTATGCGCCTTGCCAGCCCG-
CTCAGTCAGAGTTTGATYMTGGCTCAG-30; V123 forward
primer 2, 50-CTATGCGCCTTGCCAGCCCGCTCAGTCAGG-
GTTCGATTCTGGCTCAG-30; V123 forward primer
3, 50-CTATGCGCCTTGCCAGCCCGCTCAGTCAGAGTTTGATC-
AGAGTTTGATCCTGGCTTAG-30; V123 forward primer 4,
50-CTATGCGCCTTGCCAGCCCGCTCAGTCAGAATTTGATCT-
AGAATTTGATCTTGGTTCAG-30; V123 reverse primer,
Lactobacillus rhamnosus and body weight 1511
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50-CGTATCGCCTCCCTCGCGCCATCAGNNNNNNNNGGTTAC-
CGCGGCTGCTGGCAC-30; V456 forward primer, 50-CT-
ATGCGCCTTGCCAGCCCGCTCAGGCCRRCACGAGCTGAC-
GAC-30; and V456 reverse primer, CGTATCGCCTCCCTCGCGC-
CATCAGNNNNNNNNAGGCCAGCAGCCGCGGTAA-30 (where
the adapter sequences for Roche 454 FLX Titanium sequen-
cing are italicised, the linkers are underlined, NNNNNNNN
sequences designate the sample-specific eight-base barcodes
used to tag each PCR product, and bold sequences correspond
to broadly conserved 16S ribosomal RNA gene regions). V123
forward primers 1, 2, 3 and 4 were combined in 4:1:1:1 ratios.
Amplifications were performed in 50ml volumes with 2ml of
DNA extract, 50mM of deoxyribonucleotide triphosphate
(dNTP), 200 nM of forward primers (mix of forward primers
for the V123 region), 200 nM of reverse primers, 1 £ Expand
High Fidelity Reaction Buffer and 5 U/100ml of Expand High
FidelityPLUS enzyme blend (Roche Applied Science). PCR
conditions were as follows: 948C for 2 min followed by
twenty-five cycles of 948C for 30 s, 498C for 30 s, and 728C
for 1 min, ending with a final step of 728C for 7 min. After puri-
fication, pooling in equimolar amounts, the PCR products
were sequenced using the 454 FLX Titanium technology
(Microsynth AG). Raw data were analysed using the QIIME
software package(35) with default parameters, except that no
barcode correction was allowed, and reverse primers were
removed when present. The chimeras were detected and
removed using ChimeraSlayer based on reference alignment
from GreenGenes (as provided in QIIME 1.2) and default
parameters. Samples described by less than 200 sequencing
reads were excluded from the analysis. Quality-filtered
sequencing reads were analysed using the Uclust method at a
similarity threshold of 97 % identity for operational
taxonomic unit clustering. The assignment of operational
taxonomic unit into Bergey’s bacterial taxonomy was done
using the Ribosomal Database Project (RDP) Classifier with
a confidence value threshold of 60 %.
Quantification of faecal Lactobacillus rhamnosus
CGMCC1.3724
The quantification of Lactobacillus rhamnosus CGMCC1.3724
was carried out by quantitative PCR using faecal DNA
as described previously(36). Dilutions of genomic DNA of
L. rhamnosus CGMCC1.3724 were used to prepare a calibration
curve (0·02 pg–20 ng). Measured DNA quantities were con-
verted into number of genome equivalents/g of faeces based
on the molecular weight of the L. rhamnosus CGMCC1.3724
genome (3·278 fg/genome). The limit of quantification
(1·26 £ 105 genome equivalents/g of faeces) was set to 10-fold
of the measured quantitative PCR detection limit, to take into
account potential contamination during sample analysis.
Statistical analysis (clinical outcomes)
The outcome measures were analysed using ANCOVA consi-
dering changes over time in a mixed model setting treatment
and sex as independent variables while correcting for baseline
values in the model. The change in fat mass over time was
also considered as an independent variable for the ANCOVA
pertaining to changes in plasma leptin concentrations over
time. Furthermore, the effect of treatment £ sex interaction
in the model was examined. The analyses were carried out
on the intention-to-treat population utilising SAS version 9.2
(SAS Institute). Statistical significance level was set at 5 %, and
no correction of significance level was applied to adjust for mul-
tiple testing. Sample size calculation was implemented using the
statistical and power analysis software NCSS. The calculations
were primarily driven by the intention to show superiority in
mean body-weight reduction at a significance level of 5 % and
with a statistical powerof 80 %. The initial calculations suggested
that the testing of 104 subjects (fifty-two per group)was required
to get adequate statistical power. In addition, since a dropout
rate of about 12 % subjects was anticipated, we planned to
recruit 120 obese subjects (sixty per treatment group). The
sample of 104 subjects estimated above was also expected to
provide adequate power to address the important secondary
objective aiming at the detection of a between-treatment
difference in body-weight change of 1·5 kg or more during
the weight-maintenance phase of the programme.
Statistical analysis (microbiota composition)
Statistical analysis of differences between the groups with
regard to the relative abundance of individual taxonomic
groups was assessed using two-sided Wilcoxon signed-rank
tests. This analysis is consistent with the analysis on the clinical
outcomes, but slightly refined to take the microbiota data speci-
ficities into account. First, the analysis was carried out during
visits (while checking the baseline levels), since the clinical
relevance of assessing the difference between two relative abun-
dance values is very low. Second, a non-parametric approach
was preferred due to the non-normal distribution of the micro-
biota data. Moreover, the statistical analysis was carried out by
sex, based on the information gathered from the clinical out-
comes. No correction of significance level was applied to adjust
for multiple testing. However, since the analysis was carried out
on two 16S ribosomal RNA gene regions separately, only taxa
showing consistent differences in both the regions, with a
significance level of 5 % and median relative abundance greater
than or equal to 0·1% in at least one group, were examined.
Results
Improvement of Lactobacillus rhamnosus CGMCC1.3724
viability
Metabolisable sugars have been reported to improve the
survival of Lactobacillus rhamnosus strain LGG in gastrointes-
tinal conditions through ATP production(37). The survival of
LPR in simulated gastrointestinal tract conditions was assessed
in vitro by incubating the probiotic in a medium mimicking
the upper gastrointestinal tract conditions (stomach and
duodenum) containing or not containing a mixture of oligo-
saccharides and polysaccharides (fructo-oligosaccharides–
inulin 70:30). The viability of LPR was only slightly affected
under the simulated gastric conditions, whereas under duodenal
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conditions bacterial counts were dramatically decreased
(25·00 (SE 0·06) log (cfu/ml); Fig. 2). Supplementation of
0·1 % of a mixture of oligosaccharides and polysaccharides
significantly improved the resistance of LPR to duodenal con-
ditions (21·76 (SE 0·14) log (cfu/ml); Fig. 2). Based on these
results and the assumption that probiotic viability is required
for the efficacy of LPR, 300 mg of the oligosaccharide and
polysaccharide mixture were added to each ingredient cap-
sule to improve probiotic gastrointestinal tract survival and
support functionality. This dose of oligosaccharides and poly-
saccharides corresponds to a dose that is 100-fold higher than
the maximal dose tested in vitro in order to ensure optimal
survival during capsule filling and gastrointestinal transit.
Intervention trial: effects on body weight and body
composition
Variations in body weight and composition are summarised in
Table 2. The intention-to-treat analysis showed that treatment
with the LPR formulation did not significantly change weight
loss during the energy-restriction period (week 12, phase 1)
and after the weight-maintenance period (week 24, phase 2)
in the population regrouping male and female subjects. Fat
mass was also not significantly modified by the LPR formu-
lation at week 12, but it tended to be decreased by the
treatment at week 24 (changes in fat mass compared with those
observed with the placebo treatment: 21·42 (SE 0·79) kg;
P¼0·07; values are corrected for the baseline values). A signifi-
cant treatment £ sex interaction effect was observed for some
variables. Specifically, during phase 1, reductions in body
weight and fat mass were more pronounced in the LPR-treated
women than in the placebo-treated women (Table 2; changes
in body weight compared with those observed with the
placebo treatment: 21·8 (SE 0·8) kg; P¼0·02; changes in fat
mass compared with those observed with the placebo treat-
ment: 21·23 (SE 0·66) kg; P¼0·06; values are corrected for
the baseline values). Similarly, at the end of phase 2,
reductions in body weight and fat mass were more
pronounced in the LPR-treated women than in the placebo-
treated women (changes in body weight compared with
those observed with the placebo treatment: 22·6 (SE 1·1) kg;
P¼0·02; changes in fat mass compared with those observed
with the placebo treatment: 22·54 (SE 1·01) kg; P¼0·01;
values are corrected for the baseline values). The body
weight and fat mass of men were not affected by the treatment
during the two phases of the programme.
Energy balance and physiological parameters
Table 2 also summarises the values of reported daily energy
intake in each group of subjects at baseline and at the end
of the two phases of the programme (weeks 12 and 24). As
expected, the reported energy intake was reduced at week 12,
which is compatible with the dietary restriction that was
planned at the beginning of the intervention. In each group,
this reduced energy intake was maintained at week 24, and
no difference between the placebo and LPR groups and
between the sexes was observed during the two phases. How-
ever, in spite of a lack of significant differences, energy intake
seemed to be consistently lower in the LPR-treated women
in both phase 1 and phase 2, when compared with that in
women in the placebo group (Table 2).
Variations in other physiological parameters are summarised
in Table 2. The LPR treatment did not exert any significant
effect on resting energy expenditure, respiratory quotient,
heart rate and diastolic blood pressure, during both phase 1
and phase 2.
Metabolic and inflammatory plasma markers
There was no significant treatment and treatment £ sex
interaction effect on the metabolic and inflammatory plasma
markers during the programme, except for plasma leptin
(Table 3). Indeed, at week 24, a more pronounced decrease
in fasting leptin concentrations was found in the population,
including males and females in the LPR group compared
with their placebo counterparts (changes compared with those
observed with the placebo treatment: 25·9 (SE 2·3) ng/ml;
P¼0·01; values are corrected for the baseline values). This
effect of LPR on plasma leptin concentrations of the popu-
lation regrouping both the sexes was mainly driven by an
important effect in females (changes compared with those
observed with the placebo treatment: 211·0 (SE 2·9) ng/ml;
P¼0·0004; values are corrected for the baseline values).
These differences remained significant when the values were
corrected for the loss of fat mass between baseline and
week 24, suggesting that LPR decreased plasma leptin concen-
trations independently of fat mass reduction.
Microbiota analyses
The sequencing of 16S ribosomal RNA gene libraries in stool
samples collected at baseline, at week 12 and at week 24 gen-
erated, on average, 925 and 823 quality-filtered reads/sample
for the V123 and V456 regions, respectively. The following
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Fig. 2. Lactobacillus rhamnosus CGMCC1.3724 survival in the presence
of an oligofructose/inulin mix under gastric (A) and duodenal (B) in vitro
conditions. Values are means, with their standard errors represented by
vertical bars, n 4. Results represent the decrease in bacterial count when
compared with the initial bacterial count (8·85 (SE 0·02) log (cfu/ml)). ** Mean
values were significantly different from those obtained under the gastric or
duodenal condition in the absence of the oligofructose/inulin mix (P,0·01).
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number of samples per group and per time point fulfilled the
quality criteria for consideration of sequencing results: fifty-
two, fifty and forty-four samples from the placebo group at
baseline, week 12 and week 24, respectively; fifty-two, fifty
and forty-two samples from the LPR group at baseline, week
12 and week 24, respectively. Diversity rarefaction curves
reached a plateau, suggesting that the current sequencing
effort captured most of the phylogenetic diversity within the
samples (data not shown). Phylogenetic diversity was not dis-
tinguishable between the sexes (at baseline) and groups (at all
time points; data not shown). As expected, the quantification
of overall microbiota similarity between the samples,
measured based on weighted UniFrac distances, revealed a
higher similarity between the samples collected from the same
subjects at different time points than between the samples
collected from different subjects (Fig. 3). The relative abun-
dance of individual bacterial taxonomic groups was analysed
at phylum, class, order, family and genus levels, and it is
reported as median hereafter. At baseline and at weeks 12
and 24, no significant difference was detected between the
groups (LPR v. placebo). Considering the sex £ treatment
interaction observed for the anthropometric parameters
(described above), we stratified the groups by sex. At base-
line, a significant difference was detected between males
and females with regard to the relative abundance of bacteria
of the Prevotellaceae family. However, this taxonomic group
Table 2. Changes in body weight, body composition and physiological variables during the intervention programme
(Mean values with their standard errors)
Male Female
LPR formulation Placebo LPR formulation Placebo LPR formulation Placebo
Mean SE Mean SE Mean SE Mean SE Mean SE Mean SE
DWeek 12-baseline (n) 52 53 23 22 29 31
DWeek 24-baseline (n) 45 48 19 20 26 28
DBody weight (kg)
DWeek 12-baseline 24·2 3·2 23·4 2·9 24·0 3·4 24·6 3·2 24·4* 3·0 22·6 2·3
DWeek 24-baseline 25·3 4·3 23·9 4·2 25·4 4·8 25·7 4·5 25·2* 4·0 22·5 3·5
DFat mass (kg)
DWeek 12-baseline 23·51 2·39 22·76 2·83 23·20 2·70 23·05 2·90 23·75 2·14 22·55 2·80
DWeek 24-baseline 24·59 3·80 23·10 3·98 24·30 4·14 24·43 3·45 24·79* 3·60 22·16 4·11
DFat mass (%)
DWeek 12-baseline 22·16 1·94 21·82 2·40 22·07 2·06 21·95 2·36 22·23 1·88 21·72 2·46
DWeek 24-baseline 23·13 3·41 22·13 3·11 22·88 3·24 23·03 2·67 23·30* 3·57 21·48 3·28
DFat-free mass (kg)
DWeek 12-baseline 20·56 1·80 20·49 1·99 20·65 1·81 21·27 2·18 20·50 1·83 0·07 1·66
DWeek 24-baseline 20·56 1·52 20·31 1·79 20·82 1·56 20·80 1·96 20·37 1·50 0·05 1·59
DFat-free mass (%)
DWeek 12-baseline 2·15 2·00 1·87 2·49 2·10 1·99 2·09 2·46 2·19 2·04 1·72 2·54
DWeek 24-baseline 3·05 3·53 2·38 2·79 2·92 3·40 3·27 2·58 3·13 3·68 1·74 2·80
DMean daily energy
intake (kcal)
DWeek 12-baseline 2429 479 2402 433 2405 454 2435 454 2488 505 2376 423
DWeek 24-baseline 2343 440 2312 454 2341 432 2375 457 2345 455 2272 456
DMean daily energy
intake (kJ)
DWeek 12-baseline 21795 2000 21682 1812 21695 1900 21820 1900 22042 2113 21573 1770
DWeek 24-baseline 21435 1841 21305 1900 21427 1807 21569 1912 21443 1904 21138 1908
DREE (kcal/min)
DWeek 12-baseline 20·06 0·10 20·04 0·10 20·05 0·10 20·04 0·13 20·07 0·10 20·04 0·07
DWeek 24-baseline 20·06 0·11 20·02 0·11 20·02 0·13 20·01 0·09 20·08 0·09 20·04 0·13
DREE (kJ/min)
DWeek 12-baseline 20·25 0·42 20·17 0·42 20·21 0·42 20·17 0·54 20·29 0·42 20·17 0·29
DWeek 24-baseline 20·25 0·46 20·08 0·46 20·08 0·54 20·04 0·38 20·33 0·38 20·17 0·54
DRQ
DWeek 12-baseline 20·01 0·07 20·01 0·08 20·01 0·07 20·01 0·07 20·01 0·07 20·01 0·09
DWeek 24-baseline 0·00 0·09 20·01 0·08 20·02 0·10 20·02 0·09 0·02 0·08 0·00 0·07
DHR (bpm)
DWeek 12-baseline 21·5 6·9 21·7 6·6 21·8 7·9 23·0 7·3 21·3 6·2 20·8 6·1
DWeek 24-baseline 23·0 6·0 22·9 7·3 22·1 6·9 23·9 7·8 23·7 5·4 22·3 7·0
DSBP (mmHg)
DWeek 12-baseline 22·7 8·1 25·0 10·3 24·0 9·5 21·5 10·0 21·8 7·0 27·6 9·8
DWeek 24-baseline 21·2* 9·9 26·1 9·4 20·7 11·2 23·3 11·1 21·5* 9·1 28·2 7·5
DDBP (mmHg)
DWeek 12-baseline 22·1 6·6 20·8 7·5 22·1 7·7 0·2 9·8 22·0 5·9 21·4 5·4
DWeek 24-baseline 20·3 7·0 21·9 8·4 0·6 0·77 21·0 9·6 20·9 6·6 22·5 7·6
LPR, Lactobacillus rhamnosus CGMCC1.3724; REE, resting energy expenditure; RQ, respiratory quotient; HR, heart rate; bpm, beats/min; SBP, systolic blood pressure;
DBP, diastolic blood pressure.
* Mean values were significantly different from those of the placebo group (P,0·05).
M. Sanchez et al.1514
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114513003875
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 10 Jul 2017 at 15:49:32, subject to the Cambridge Core terms of use, available at
Table 3. Changes in metabolic and inflammatory markers during the intervention programme
(Mean values with their standard errors)
Male Female
LPR Placebo LPR Placebo LPR Placebo
Mean SE Mean SE Mean SE Mean SE Mean SE Mean SE
DWeek 12-baseline (n) 52 53 23 22 29 31
DWeek 24-baseline (n) 45 48 19 20 26 28
DFasting glucose (mmol/l)
DWeek 12-baseline 0·2 0·7 0·1 0·5 0·0 0·3 20·1 0·4 0·4 0·9 0·2 0·6
DWeek 24-baseline 0·2 0·8 0·0 0·5 0·1 0·4 20·2 0·3 0·3 1·0 0·2 0·6
DFasting insulin (pmol/l)
DWeek 12-baseline 23·0 30·8 28·0 27·2 0·5 28·3 27·1 35·7 25·9 33·1 28·6 18·8
DWeek 24-baseline 214·1 19·6 212·7 25·2 212·8 17·7 220·9 229·4 215·2 21·3 26·7 20·2
DTotal cholesterol (mmol/l)
DWeek 12-baseline 20·3 0·6 20·2 0·5 20·2 0·5 20·2 0·4 20·4 0·7 20·2 0·6
DWeek 24-baseline 20·2 0·5 20·1 0·5 20·2 0·5 20·2 0·4 20·2 0·4 20·0 0·6
DTAG (mmol/l)
DWeek 12-baseline 20·1 0·4 20·1 0·3 20·1 0·5 20·1 0·4 20·1 0·3 0·0 0·3
DWeek 24-baseline 20·0 0·3 20·1 0·3 0·0 0·5 20·1 0·3 20·1 0·2 20·1 0·3
DLDL (mmol/l)
DWeek 12-baseline 20·2 0·5 20·1 0·4 20·1 0·4 20·2 0·4 20·2 0·5 20·1 0·4
DWeek 24-baseline 20·2 0·4 20·1 0·4 20·3 0·4 20·2 0·4 20·1 0·4 20·1 0·4
DHDL (mmol/l)
DWeek 12-baseline 20·1 0·2 20·0 0·2 0·0 0·1 0·0 0·1 20·2 0·3 20·1 0·2
DWeek 24-baseline 0·0 0·2 0·1 0·2 0·1 0·2 0·1 0·1 20·0 0·3 0·1 0·2
DLeptin (ng/ml)
DWeek 12-baseline 27·0 8·0 24·8 11·7 22·8 4·2 23·0 4·4 210·2 8·7 26·2 15·1
DWeek 24-baseline 28·1* 10·4 20·8 12·1 23·5 4·1 21·8 5·3 211·3* 12·2 20·1 15·4
DAdiponectin (ng/ml)
DWeek 12-baseline 2149·8 1641·6 15·2 1698·4 25·3 1797·3 393·3 1800·8 2282·7 1532·0 2271·6 1587·9
DWeek 24-baseline 439 1669·7 1073·6 1974·7 157·4 1190·4 1242·2 2367·7 638·6 1935·2 948·8 1662·6
DGlycerol (mmol/l)
DWeek 12-baseline 20·00 0·02 20·01 0·02 0·00 0·01 0·00 0·01 0·00 0·02 20·01 0·03
DWeek 24-baseline 20·00 0·02 20·01 0·03 20·00 0·01 0·00 0·02 20·00 0·03 20·02 0·03
DNEFA (mmol/l)
DWeek 12-baseline 20·01 0·13 20·02 0·18 0·01 0·14 20·01 0·19 20·02 0·13 20·03 0·19
DWeek 24-baseline 20·05 0·16 20·07 0·15 20·00 0·14 20·05 0·12 20·08 0·17 20·08 0·17
Db-Hydroxybutyrate (mmol/l)
DWeek 12-baseline 16·9 63·9 14·1 89·6 9·5 43·0 20·1 118·0 22·6 76·4 9·4 62·1
DWeek 24-baseline 15·8 109·4 5·0 56·1 44·9 117·5 18·2 66·8 24·7 100·5 24·7 45·7
DLBP (mg/ml)
DWeek 12-baseline 0·1 3·7 20·5 4·2 0·0 3·0 21·4 2·7 0·1 4·1 0·1 5·0
DWeek 24-baseline 0·1 3·6 0·2 5·1 0·6 2·2 20·2 5·0 20·2 4·4 0·5 5·3
DCRP (mg/l)
DWeek 12-baseline 0·1 4·4 21·2 5·4 20·7 4·8 20·8 2·6 0·7 4·1 21·5 6·8
DWeek 24-baseline 20·1 4·3 20·5 5·7 21·5 4·3 0·9 5·6 0·8 4·2 21·5 5·7
LPR, Lactobacillus rhamnosus CGMCC1.3724; LBP, lipopolysaccharide-binding protein; CRP, C-reactive protein.
* Mean values were significantly different from those of the placebo group (P,0·01).
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represented only a tiny fraction of the global microbiota (0 %
in males v. 0·4 % in females; with P¼0·03 and P¼0·05 for V123
and V456, respectively). In males, the LPR treatment did not
affect the microbiota composition at any time point, except
for a low-abundance unclassified taxonomic group belonging
to the Firmicutes phylum that was quantified at week 12 at a
slightly higher relative abundance in the placebo group than
in the LPR group (0·1 % in the placebo group v. 0 % in the
LPR group, as detected by V123 with P¼0·01; 0·5 % in the pla-
cebo group v. 0·2 % in the LPR group, as detected by V456
with P¼0·02). Interestingly, in females, the relative abundance
of bacteria of the Lachnospiraceae family, a dominant taxo-
nomic group, was consistently reduced in the LPR group at
week 12 (36·9 % in the placebo group v. 30·3 % in the LPR
group, as detected by V123 with P¼0·009; 32·9 % in the pla-
cebo group v. 24·5 % in the LPR group, as detected by V456
with P¼0·001) and week 24 (38·2 % in the placebo group v.
27·6 % in the LPR group, as detected by V123 with P¼0·001;
32·6 % in the placebo group v. 24·5 % in the LPR group, as
detected by V456 with P¼0·03). The results obtained for the
relative abundance of bacteria of the Lachnospiraceae family
with V123 are shown in Fig. 4. Differences in the abundance
of members of the Lachnospiraceae family were essentially
driven at the genus level by bacteria classified in the Roseburia
genus and unclassified in the Lachnospiraceae family, although
none reached the statistical significance threshold (data not
shown). The only other significant difference detected between
the LPR-treated and placebo-treated females was a reduction in
the abundance of bacteria of the Subdoligranulum genus
detected at week 12 (4·8 % in the placebo group v. 2·9 % in
the LPR group, as detected by V123 with P¼0·01; 4·1 % in the
placebo group v. 2·5 % in the LPR group, as detected by V456
with P¼0·02). This taxonomic group belongs to the closely
related Ruminococcaceae family.
Faecal Lactobacillus rhamnosus CGMCC1.3724 detection
Faecal LPR was quantified by real-time PCR using
strain-specific primers and TaqMan probes. At week 12, the
percentage of subjects with detectable LPR in the faeces
increased to 90 % in the treated group, whereas in the placebo
group, only 10 % of the subjects showed LPR-positive signals
(Fig. 5; Fisher’s exact test P,0·001). A similar percentage of
subjects with detectable faecal LPR were observed at week
24 (Fig. 5; Fisher’s exact test P,0·001). The faecal abundance
of LPR in the LPR-positive subjects in the treated group was
similar at weeks 12 and 24 (week 12: 7·7 (SE 1·1) £ 106
genome equivalents/g faeces; week 24: 5·4 (SE 0·9) £ 106
genome equivalents/g faeces). At week 12, the percentage
of detectable faecal LPR was similar in males and females
(90·9 and 90·0%, respectively; Fisher’s exact test P¼1), whereas
at week 24, it was slightly lower in males than in the females
(77·8 and 85·7%, respectively; Fisher’s exact test P¼0·424).
Dropout rate
As shown in Fig. 1, the dropout rate was less than 25 %.
The main reason given by the dropouts was the lack of
time. There was one participant who was excluded because
of the poor compliance to the treatment (more than three
consecutive days without the treatment). No adverse events
were reported as a dropout reason. There was no significant
difference between the two groups for the dropout rate.
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Fig. 4. Faecal Lactobacillus rhamnosus CGMCC1.3724 (LPR) content in
male (X) and female (W) subjects in the placebo and LPR groups measured
at baseline, week 12 and week 24. Data represent individual faecal contents.
A 2 log (copies/sample unit) value was arbitrarily attributed to measures below
the quantification limit (QL) as defined in the Methods section. Zero values
correspond to subjects with undetectable faecal LPR by quantitative PCR.
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Fig. 3. Evolution of the relative abundance (%) of bacteria of the Lachnospiraceae family in (a) males and (b) females in the placebo group (W) and the probiotic
group (X) at week 0, week 12 and week 24. Values are medians, with their standard errors represented by vertical bars. ** Median values were significantly differ-
ent from those observed with the placebo treatment (P,0·01).
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Discussion
Obesity is a multifactorial problem that requires the consider-
ation of numerous relevant factors when designing a potential
successful intervention. Recent literature provides evidence
that gut microflora might be involved in the aetiology of obesity.
In this regard, we conducted the present study to evaluate
the impact of a LPR formulation on body weight and fat
mass in obese men and women.
During the energy-restriction period, administration of the
LPR formulation did not significantly decrease the body
weight or fat mass of an obese population regrouping men
and women. However, at the end of the weight-maintenance
phase, the LPR group tended to lose more fat mass than the
placebo group. A subgroup analysis revealed that the
observed trend was mainly driven by a significant reduction
in fat mass in women. Analysis of the sex-specific results
revealed significantly higher body-weight and fat mass losses
promoted by the LPR treatment at the end of the energy-
restriction phase and after the weight-maintenance phase in
women but not in men. Measurements of the abundance
and prevalence of LPR in faeces of the placebo and LPR
groups indicated good treatment compliance and did not
reveal any significant difference between the sexes.
Our clinical experience indicates that men are generally
more prone to respond to a negative-energy balance interven-
tion than women, be it in response to an exercise-training
programme(38), a diet–exercise programme(39), or a session of
exercise and of mental work(40). This is concordant with the
results of the present study showing higher weight loss in
men in the placebo group than in the women. The fact that
the LPR supplementation abolished this difference suggests
that the gut microbiota may be involved in the LPR-induced
effect. At baseline, only a single low-abundance taxo-
nomic group (Prevotellaceae) showed significantly different
abundance levels between the sexes. The small difference
observed in the present study between men and women is in
agreement with the findings of previous studies investigating
sex-associated signatures, generally reporting only minor
and inconsistent differences(41–43). Consequently, the baseline
microbiota composition is unlikely to explain the sex-specific
responses to the LPR treatment. Interestingly, whereas the LPR
treatment did not induce any major change in the microbiota
composition in men, the abundance of bacteria of the
Lachnospiraceae family was substantially and significantly
reduced by the LPR treatment in women at both week 12
and week 24. The Lachnospiraceae family belongs to the
Firmicutes phylum, a taxonomic group that has previously
been reported to be positively associated with obesity(6,9,10).
However, associations between microbiota composition and
obesity show only limited consistency between independent
studies(44), making it difficult to identify specific bacterial
groups that could contribute to the obese phenotype. Both posi-
tive and negative associations have been reported between the
intestinal levels of Lachnospiraceae family members and
obesity(45,46). Taken together, these observations suggest that
bacteria of the Lachnospiraceae family might play a role in
obesity and that the seeming contradictions may be due to
differences in hosts (human and mouse), conditions (age,
diet, etc.) and techniques used to measure the microbiota com-
position. Interestingly, alterations in the abundance of bacteria
of the Lachnospiraceae family (enrichment of an unknown
Lachnospiraceae family member and reduction in the abun-
dance of the Roseburia species) and an increased abundance of
an unknown bacterium closely related to the Subdoligranulum
genus have also been reported in association with type 2
diabetes in a human metagenomic study(12). Similar results
have been obtained in another type 2 diabetes human study
carried out using 16S profiling(47), suggesting a progressive
modification of the microbiota composition from obese individ-
uals losing weight on dietary restriction to obese individuals
with type 2 diabetes through healthy obese individuals. It is
worth noting that the taxonomic groups identified in the present
study are among the most important intestinal producers of
SCFA derived from carbohydrate fermentation(48). Among
other mechanisms, these compounds have been proposed as
mediators of the interaction between gut microbes and the
host in the regulation of energy metabolism(49,50).
In addition to its effect on weight and fat mass loss, the
LPR formulation reduced by about 25 % circulating leptin
concentrations at the end of the weight-maintenance phase.
Statistical analysis correcting for fat mass loss between
baseline and week 24 revealed that circulating leptin concen-
trations were regulated independently of fat mass reduction.
These data suggest that LPR could lower plasma leptin
concentrations directly or through changes in the microbiota
composition or function. Interestingly, the relative abundance
of bacteria of the Lachnospiraceae family has been reported to
be positively associated with circulating leptin concentrations
in mice after weight loss(45). Reductions in plasma leptin
concentrations were preferentially observed in women who
had about 3-fold higher baseline leptin concentrations than
in men (Table 1), suggesting that LPR was more prone to
reduce leptin concentrations in elevated leptin concentration
conditions. Since the SCFA stimulate leptin production in
adipocytes(51), the reduction in the abundance of SCFA
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Fig. 5. Comparisons of the weighted UniFrac distances between samples ( )
collected during each period (W0, baseline; W12, week 12; W24, week 24)
and between paired samples collected from the same subjects ( ) at
the end of the weight-loss period (W12, week 12) and the end of the trial
(W24, week 24). Values are means, with their standard errors represented
by vertical bars.
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producers belonging to the Lachnospiraceae family and
Subdoligranulum genus observed in the LPR-treated women
may explain the reduction in circulating leptin concentrations.
No significant changes in other physiological, metabolic
and inflammatory markers of the metabolic syndrome were
observed in the treated group. The absence of changes in
the plasma metabolic and inflammatory markers may be
explained by the fact that the inclusion and exclusion criteria
used in the present study prevented the recruitment of sub-
jects displaying an unhealthy metabolic profile. This does
not exclude that LPR can improve the condition of obese indi-
viduals exhibiting the metabolic syndrome, but the present
results suggest that these potential benefits are at least limited
in metabolically healthy individuals.
It is well established that a major difficulty related to obesity
management is the capacity to maintain body weight after sig-
nificant weight loss. This is concordant with the findings of
studies showing that body-weight and fat mass losses favour a
greater-than-predicted decrease in energy expenditure(52,53)
and a significant increase in hunger feelings(54). Thus, in a
reduced obese state, it is essential that some lifestyle changes be
made to compensate for the trend towards weight regain. In the
present study, recommendations of healthy eating at the end of
the weight-loss phase (phase 1) appeared to be successful in
men in the placebo group as well as in the two groups of subjects
who continued the LPR supplementation. In contrast, fat regain
was observed in women in the placebo group during the
weight-maintenance phase, suggesting that probiotics may help
obese women to maintain healthy body weight.
It is important to mention that there was probably no
independent prebiotic effect in the LPR group considering that
600 mg of daily dose of inulin and oligofructose (70:30, v/v)
included in the LPR capsules are not sufficient to exert an
effect on weight loss. In contrast, in a study, a daily dose of
16 g of inulin–oligofructose (50:50, v/v) in obese women led
to changes in the gut microbiota composition that were of a
magnitude similar to that observed in the present study, but
of different orientation or in different taxonomic groups, and
without a significant effect on body weight(55). Even if a slight
impact on gut microbiota composition cannot be excluded, it
is unlikely that weight loss observed in the LPR group can be
attributed to the prebiotic mix contained in the capsules.
Fibres were used to increase probiotic survival in the gastric
(low pH) and duodenal (presence of bile salts) conditions,
thereby supporting probiotic functionalities.
In summary, the present study demonstrates that LPR
supplementation can accentuate body-weight loss in women
submitted to energy restriction. This effect persisted in the
subsequent maintenance phase when energy restriction was
not imposed further. Thus, LPR supplementation seems to
help obese women to maintain healthy body weight. Further
research is needed to provide mechanistic explanations of
this effect on energy balance.
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